Literature DB >> 3926292

Intra-arterial infusion chemotherapy as an induction therapy in multidisciplinary treatment for locally advanced breast cancer. A long-term follow-up study.

H Koyama, Y Nishizawa, T Wada, T Kabuto, E Shiba, T Iwanaga, T Terasawa, A Wada.   

Abstract

A multidisciplinary treatment including intra-arterial infusion chemotherapy as an induction therapy was administered to 55 patients with locally advanced breast cancer. Intra-arterial chemotherapy conducted preoperatively produced marked responses in primary and lymph node lesions with 78% complete + partial response (CR + PR), subsequently permitting extended radical mastectomy. Histologic examination of resected specimens also revealed that 33% of the patients had no viable cancer cells remaining in their lesions. Five-year and 10-year survival rates were 57% and 41%, respectively, compared with 24% and 18%, respectively for the 17 patients of historic control. Patients showing better local responses to intra-arterial chemotherapy had longer survival time with less frequent local recurrences. Intra-arterial chemotherapy is an effective modality for the treatment of locally advanced breast cancer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3926292     DOI: 10.1002/1097-0142(19850815)56:4<725::aid-cncr2820560404>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Management of locally advanced breast cancer.

Authors:  P I Borgen
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

2.  Toxicity of intra-arterial doxorubicin in locally advanced breast cancer.

Authors:  C J Twelves; M A Chaudary; J Reidy; M A Richards; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma.

Authors:  David T Tse; Andrea L Kossler; William J Feuer; Pasquale W Benedetto
Journal:  Ophthalmology       Date:  2013-04-09       Impact factor: 12.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.